Main Industry
Biotechnology
Main Product/Service
1. Trastuzumab Biosimilar
2. CDMO Services
3. CRM197 Carrier Protein
4. COVID-19 Antigen Rapid Test
2. CDMO Services
3. CRM197 Carrier Protein
4. COVID-19 Antigen Rapid Test
Founded Year
2012
Unified Business No.
54150737
Status
Active
Number of Employees
40
Total Paid-in
Capital
3,061,895,760 (NT$)
Location of Company
Taiwan
, New Taipei City
Exit Status
OTC listing(2019)
Year of establishment, company status, responsible person, paid-in capital amount, and registered address are sourced from the "Commerce Industrial Services Portal, Department of Commerce, MOE. Exit status refers to various situations, including emerging stock exchanges (e.g., potential exits), mergers and acquisitions (M&A), and IPOs. The overseas development countries are collected through information provided by startups themselves and the information filled in when registering for matchmaking events. Therefore, the information cannot be updated in real time. If you wish to make corrections, please email findit.tier@gmail.com. Thank you.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
EirGenix Inc., health is important for all people. Under this belief, EirGenix established two business units to achieve the goal. One is contract development and manufacturing operation unit where EirGenix helps clients to manufacture their biologics; the other is the product development operation unit where they hope to fully apply theirteam's experience and knowledge on biologics from biosimilars, biobetters to new drugs. EirGenix's goal is that every patient can afford high-quality biopharmaceutical drugs.
